Dispatch Bio Starts GI Cancer Trial After FDA Fast Track
PHILADELPHIA, PA — Dispatch Bio has dosed the first patient in a Phase 1 trial of DISP-10 for advanced gastrointestinal cancers, moving its experimental solid-tumor immunotherapy into human testing as …
Dispatch Bio Starts GI Cancer Trial After FDA Fast Track Read More